Company News For Dec 27, 2019

• Shares of Can-Fite BioPharma Ltd. (CANF - Free Report) surged 30.5% after the company announced its strategic partnership with Univo to develop cannabinoid-based products is ongoing.
• Shares of Immunomedics, Inc. gained 5.7% after the company announced that the FDA had accepted for filing the company's BLA seeking accelerated approval of sacituzumab govitecan to treat metastatic triple-negative breast cancer.
• Shares of Spring Bank Pharmaceuticals, Inc. declined 66.8% after the company reported that it has stopped the dosing of inarigivir patients in Phase 2 program.
• Shares of QIAGEN N.V. (QGEN - Free Report) declined 20.6% after the company announced that it would not be acquired and will stay a standalone business.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>